Leah Kuntz

Recognize postpartum psychosis fast: early signs, key risk factors, OCD vs delusions, and evidence-based lithium-centered treatment for urgent care.

Explore suicide prevention in psychiatry—risk assessment, treatment challenges, and emerging research. Submit your case or CME for August 2026.

Fitbit and Google Health app data feed Amae clinicians real-time sleep, physical activity, and heart rate variability signals to spot relapse early in severe mental illness.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.

Check out the pipeline updates from July!

New analysis shows COMP360 psilocybin sessions for PTSD stay mostly silent, with nondirective support boosting safety and autonomy.

Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.

ASCP updates spotlight ketamine safety guardrails, at‑home agitation therapy, psilocybin phase 3 momentum, and biomarker-driven precision psychiatry.

Top 2026 psychiatry conference takeaways: mixed-feature bipolar care, GLP-1 addiction trials, schizophrenia adherence, TD gaps, AI prodrome screening.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

FDA grants Fast Track to Acadia’s remlifanserin for Alzheimer disease psychosis, targeting hallucinations and delusions as RADIANT trial advances toward 2026 data.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.

Midlife sleep trouble predicts poorer well-being 9 years later, especially for women. Here's why clinicians should ask about sleep and menopause triggers.

Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.

Check out the pipeline updates from May!

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.